Although EGF–EGFR signaling is only one of several pathways involved in cancer cell proliferation and motility, the respective effects of EGF and Rab25 on integrin localization revealed in the present study may partially explain the diverse effects of EGFR-targeting drugs. The gene discussed is EGF; the disease is cancer.